-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LNS-8801 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LNS-8801 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LNS-8801 in Gastric Cancer Drug Details: LNS-8801 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LNS-8801 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LNS-8801 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LNS-8801 in Metastatic Pancreatic Cancer Drug Details: LNS-8801 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IVS-3001 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IVS-3001 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IVS-3001 in Metastatic Renal Cell Carcinoma Drug Details: Gene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Arlocabtagene Autoleucel in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Arlocabtagene Autoleucel in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Arlocabtagene Autoleucel in Relapsed Multiple Myeloma Drug Details: Arlocabtagene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Arlocabtagene Autoleucel in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Arlocabtagene Autoleucel in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Arlocabtagene Autoleucel in Refractory Multiple Myeloma Drug Details: Arlocabtagene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – G-207 in Gliosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - G-207 in Gliosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. G-207 in Gliosarcoma Drug Details: G-207 is under development for high-grade glioma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Uremic (Renal) Pruritus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-547 in Uremic (Renal) Pruritus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-547 in Uremic (Renal) Pruritus Drug Details: EP-547 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nedisertib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nedisertib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nedisertib in Solid Tumor Drug Details: Nedisertib (M-3814, MSC-2490484A) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-501 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-501 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-501 in Pancreatic Cancer Drug Details: CBP-501 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imlifidase in Guillain-Barre Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imlifidase in Guillain-Barre Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imlifidase in Guillain-Barre Syndrome Drug Details: Imlifidase (Idefirix) is an immunosuppressive...